Cocrystal Pharma, INC 8-K filings

Cocrystal Pharma announced a $5 million private placement with existing investor OPKO Health, Inc., to advance its antiviral drug candidate programs.

Cocrystal Pharma, Inc. announced the results of its 2026 Annual Meeting of Stockholders, including the election of five directors and ratification of its independent auditor.

Cocrystal Pharma, Inc. announced the immediate appointment of James Sapirstein as Chief Executive Officer, effective June 3, 2026, alongside a new stock option grant.

Cocrystal Pharma has appointed James Sapirstein as its new Chief Executive Officer, effective immediately, leveraging his extensive antiviral development experience.

Cocrystal Pharma announces the discovery of novel direct-acting antivirals demonstrating pan-viral activity against hantavirus, bunyavirus, and influenza.

Cocrystal Pharma presented positive Phase 1 data and clinical advancement for its oral norovirus candidate, CDI-988, at ICAR 2026.

Cocrystal Pharma has been granted FDA Fast Track designation for its oral antiviral candidate, CDI-988, aimed at treating and preventing norovirus infections.

Cocrystal Pharma announced its 2025 financial results and provided updates on its antiviral drug-development programs, including the ongoing Phase 1b norovirus challenge study for CDI-988.

Cocrystal Pharma, Inc. announced the passing of Dr. Anthony Japour, a member of its board of directors, on March 10, 2026.

Cocrystal Pharma announced its oral norovirus protease inhibitor, CDI-988, will be presented at the International Society for Antiviral Research Conference 2026, highlighting its potential for norovirus and coronavirus treatment.

Cocrystal Pharma's Compensation Committee approved non-qualified stock options for directors, executive officers, and a consultant, alongside a cash award for Dr. Roger Kornberg.

Cocrystal Pharma, Inc. received Institutional Review Board approval to initiate a Phase 1b human challenge study for CDI-988, its norovirus prevention and treatment drug candidate.

Cocrystal Pharma's CFO and Co-CEO, James Martin, will present a company overview and clinical progress update at the Noble Capital Markets 21st Emerging Growth Equity Conference on December 3, 2025.

Cocrystal Pharma reported reduced Q3 2025 net losses and R&D expenses, secured new funding, and advanced its norovirus and influenza antiviral programs.

Cocrystal Pharma, Inc. announced a private placement where four insiders purchased $1.03 million in units, each consisting of common stock and warrants, demonstrating confidence in the company's antiviral clinical programs.

Cocrystal Pharma received a $500,000 NIH SBIR Phase I award to advance its novel oral broad-spectrum influenza antiviral candidate.

Cocrystal Pharma, Inc. closed a registered direct offering and concurrent private placement, securing $4.75 million upfront and up to $8.3 million more from warrants.

Cocrystal Pharma announced its President and co-CEO presented positive Phase 1 data for its lead norovirus antiviral candidate, CDI-988, at a major scientific conference.

Cocrystal Pharma, Inc. announced a registered direct offering and concurrent private placement to raise up to $13 million for working capital and general corporate purposes.

Cocrystal Pharma reported reduced net losses for Q2 2025 and provided positive updates on its norovirus and influenza antiviral programs, despite a significant decrease in cash reserves.

Cocrystal Pharma announced positive safety and tolerability data from its Phase 1 study of pan-viral inhibitor CDI-988, supporting its continued development for norovirus.

Cocrystal Pharma, Inc. announced that its first-in-class pan-viral protease inhibitor CDI-988, targeting norovirus, will be featured in an oral presentation at the 9th International Calicivirus Conference, detailing Phase 1 study results.

Cocrystal Pharma, Inc. announced that its stockholders approved the election of all six director nominees, ratified Weinberg & Company as its independent auditor, and adopted the 2025 Equity Incentive Plan at its 2025 Annual Meeting.

Cocrystal Pharma, Inc. has amended its bylaws to reduce the quorum requirement for stockholder meetings to one-third of the aggregate voting power of outstanding shares.

Cocrystal Pharma, Inc. announced that its broad-spectrum protease inhibitor CDI-988, a novel norovirus antiviral, will be featured in an oral presentation discussing Phase 1 results at the 2025 Military Health System Research Symposium.

Cocrystal Pharma, Inc. announced that its investigational drug candidate CC-42344 exhibited strong antiviral activity against the highly pathogenic 2024 H5N1 avian influenza strain, proving approximately 1,000-fold more potent than Tamiflu.

Cocrystal Pharma reports its Q1 2025 financial results and provides updates on its antiviral product pipeline, highlighting progress with CDI-988 and CC-42344.

Cocrystal Pharma announces that its antiviral drug candidate CDI-988 demonstrates potent activity against the emerging GII.17 norovirus variants, which have become prevalent in the U.S. and Europe.

Cocrystal Pharma, Inc. presented to members of the investment community on April 23, 2025, with a copy of the slide presentation furnished as an exhibit.

Cocrystal Pharma's Board of Directors approved the 2025 Equity Incentive Plan to incentivize employees, consultants, officers, and directors through equity-based awards.